Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
In this Italian, multicenter, randomized, double-blind, placebo controlled, phase III study
the efficacy of exemestane will be evaluated in addition to the standard front line treatment
in patients with hormone-receptor-positive high grade serous or endometrioid Epithelian
Ovarian Cancer (EOC). The patients enrolled in the EXPERT trial will receive exemestane or
placebo in addition to standard treatment. Patients and investigators will be blinded to
study treatment.
The hypothesis underlying the proposed clinical trial is that exemestane added to standard
first line therapy will significantly prolong median progression free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
Ente Ospedaliero Ospedali Galliera
Collaborators:
Federation of Italian Cooperative Oncology Groups Fondazione Policlinico Universitario Agostino Gemelli IRCCS Istituto Di Ricerche Farmacologiche Mario Negri